BGB-24714
- Generic Name
- BGB-24714
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 210
- Registration Number
- NCT05381909
- Locations
- 🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸Banner Md Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Scri Florida Cancer Specialists North, Saint Petersburg, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath